Navigation Links
NUVO in Medical News

Nuvo Announces 2009 second quarter financial results

... MISSISSAUGA, ON, Aug. 7 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm...ation for the Study of Pain; and, - nuvo had $26.3 million in cash and cash equivalents at ...nsaid Plus. Subsequent to the quarter end, nuvo received additional proceeds of $5.7 milli...

FDA extends review of Pennsaid(R) diclofenac sodium topical solution

...eading global provider of healthcare products, and nuvo Research Inc. (TSX:NRI), a Canadian drug developme... of November 4, 2009. During the review process, nuvo provided the FDA with supplemental information, wh... review process," stated Dan Chicoine, Chairman of nuvo Research. "Covidien is committed to the future s...

Nuvo Research and Covidien sign U.S. license and development agreement for Pennsaid(R) and Pennsaid Plus(R)

... MISSISSAUGA, ON, June 16 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI) a Canadian drug developme...oidal anti-inflammatory drug ("NSAID") candidates. nuvo has been advised by the U.S. Food and Drug Adminis...he terms of the license and development agreement, nuvo will receive an up-front, non-refundable payment o...

Nuvo announces 2009 first quarter financial results

...MISSISSAUGA, ON, April 30 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm...the PDUFA Date) by which the FDA intends to advise nuvo on Pennsaid's approvability - Recei...ntermann, President and Chief Executive Officer of nuvo Research. Financial Results: (thousa...

Pennsaid(R) Phase 3 study results to be published in leading international PAIN journal

...MISSISSAUGA, ON, April 23 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm...n-class product available in the United States." nuvo resubmitted its application for Pennsaid approval ...9. The FDA has indicated that it intends to advise nuvo of its decision regarding the approval of Pennsaid...

Nuvo announces 2008 fourth quarter and year-end financial results

... MISSISSAUGA, ON, Feb. 27 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm...ug User Fee Act by which the FDA intends to advise nuvo on Pennsaid's approvability - Annou...ntermann, President and Chief Executive Officer of nuvo Research. Financial Results: (thousands...

Nuvo's High Throughput Experimentation Platform Selected as 2009 Edison Award Finalist

... MISSISSAUGA, ON, Feb. 24 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm...edge research and development that we are doing at nuvo Research," said John M. Newsam, fqubed's President...n Awards, visit www.edisonawards.com . About nuvo Research Inc. ...

FDA Accepts Nuvo's Resubmission For Pennsaid(R)

... -Provides nuvo with PDUFA date of August 5, 2009- MISSISSAUGA, ON, Feb. 19 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm...r. The FDA has indicated that it intends to advise nuvo of its decision regarding Pennsaid approvability b...

Nuvo Research Announces Successful Completion Of All Pennsaid(R) Studies

... MISSISSAUGA, ON, Jan. 28 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm... provide the FDA with the data it requires to give nuvo final, unconditional approval to market Pennsaid i.... Henrich Guntermann, President and CEO of Nuvo. nuvo is in the process of finalizing its resubmission f...

Nuvo Research subsidiary signs collaboration agreement with Fortune Global 500 company

... MISSISSAUGA, ON, Nov. 25 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm...entary experience with skin-applied products." nuvo acquired fqubed in 2005 to increase its ability to... products for delivery to or through the skin. The nuvo subsidiary has discovered molecular penetration en...
NUVO in Medical Technology

Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference

... MISSISSAUGA, ON, Oct. 27 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm...ollege of Rheumatology Scientific Meeting provides nuvo with a forum to share our compelling Pennsaid clin...served with Pennsaid than oral diclofenac. About nuvo Research Inc. ...

Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172

... - Phase 2 development to begin in late 2008 or in early 2009 - SAN CARLOS, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced positive results from the Phase 1b proof-of-concept trial of NU172, demonstrating that the direct thrombin inhibitor rapidly produce...

Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172

... - Phase 2 trial expected to begin in late 2008 or early 2009 - SAN CARLOS, Calif., June 4 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced that it has enrolled the first patient in a single-center, Phase 1b trial to determine the safety, tolerability and pharmacokinetics...

Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172

... 2 development to begin late in 2008 or in early 2009 - SAN CARLOS, Calif., April 29 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced positive results from the Phase 1 proof-of-concept trial (n=30) of NU172, demonstrating that the thrombin-inhibitor achieved rapid o...

Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models

... SAN CARLOS, Calif., April 14 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced preclinical data demonstrating the mechanism of action and the potent therapeutic activity of NU206 (R-spondin1) in chemotherapy or ...

Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development

... -Webcast to Be Held at 4:30 p.m. ET today- SAN CARLOS, Calif., March 17 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced that data from the Phase 2 program in catheter occlusion (CO), known as SONOMA-3 (Speedy Opening of Non-functional and Occluded cath...

Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172

... SAN CARLOS, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced that it has enrolled the first patient in a single-center, Phase 1 trial to determine the safety, tolerability and pharmacokinetics ...

Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke

... SAN CARLOS, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced dosing of the first patient in a Phase 2 proof-of-concept trial of alfimeprase for the treatment of acute ischemic stroke. Nuvelo ...

Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call

... SAN CARLOS, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced that it will hold a webcast and conference call to discuss results of the Phase 3 SONOMA-2 (Speedy Opening of Non-functional and Occ...

Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion

...er, More Concentrated Dose of Alfimeprase - SAN CARLOS, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced enrollment of the first patient in the SONOMA-3 (Speedy Opening of Non-functional and Occluded catheters with Mini-dose Alfimeprase-...
NUVO in Biological Technology

ARCA biopharma to Present at 27th Annual JPMorgan Healthcare Conference

...a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, and Nuvelo, Inc. (Nasdaq: nuvo ) today announced that Richard Brewer, ARCA's president and chief executive officer, will present at the 27th Annual JPMorgan Healthcare Conference on...

Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma

... SAN CARLOS, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced that the stockholders of Nuvelo have approved the issuance of Nuvelo Common Stock pursuant to the merger agreement dated September 2...

Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers

... SAN CARLOS, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced positive results from the Phase 1 trial of recombinant, secreted protein, NU206, the company's lead compound from its Wnt Therapeuti...

Nuvelo and ARCA biopharma Advance Toward Completion of Merger

... SAN CARLOS, Calif. and BROOMFIELD, Colo., Dec. 1 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) and ARCA biopharma, Inc., a privately-held biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovas...

ARCA biopharma to Present at JMP Securities Healthcare Focus Conference

... JMP Securities Healthcare Focus Conference on Monday, October 6, 2008, at 3:00 p.m. EDT in New York City. ARCA biopharma and Nuvelo, Inc. (Nasdaq: nuvo ) announced on September 25, 2008 that they have entered into a definitive merger agreement, expected to create a cardiovascular-focused, late-stage b...

Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company

... at 8:30 a.m. EDT SAN CARLOS, Calif. and BROOMFIELD, Colo., Sept. 25 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) and ARCA biopharma, Inc., a privately-held biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovas...

Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers

... SAN CARLOS, Calif., July 29 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced that it has enrolled the first subject in a single-center, Phase 1 trial of recombinant, secreted protein, NU206, the company's lead...

Nuvelo Reports Second Quarter 2008 Financial Results

... SAN CARLOS, Calif., July 23 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced second quarter 2008 financial results and accomplishments. For the second quarter ended June 30, 2008, Nuvelo reported a net loss ...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...CVTX ) EDWARDS LIFESCIENCES CORP (NYSE: EW ) MEDICINES COMPANY (NASDAQ: MDCO ) MOMENTA PHARMACEUTICALS INC (NASDAQ: MNTA ) NUVELO INC (NASDAQ: nuvo ) PAR PHARMACEUTICAL COS INC. (NYSE: PRX ) SANGAMO BIOSCIENCES INC. (NASDAQ: SGMO ) SCIELE PHARMA INC. (NASDAQ: SCRX ) SPEEDEL HOLDING AG-REG (...

Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008

... SAN CARLOS, Calif., May 8 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced first quarter 2008 financial results and provided an updated outlook for 2008. For the first quarter ended March 31, 2008, Nuvelo ...
Other Tags
(Date:1/22/2015)... 2015 Gabe’s Chemo Duck Program is pleased to ... app ever created for kids with cancer. The Chemo Duck App, ... is filled with enjoyable games to help children of all ages ... app helps to keep kids entertained, educated and at ease while ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David Leadbetter ... to bestow a Juvent Sports Achievement award upon an ... The award commemorated and congratulated McKitrick for her record ... her first amateur tournament in 1979 and most recently ...
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
(Date:12/24/2014)... its launch in December 2014, the 1U™ app ... trying to remember their usernames and passwords through replacing the ... To assist people who have struggled to remember usernames and ... and focuses on redefining identity, announced today that it is ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... the addition of the "The Global Watermarking ... http://photos.prnewswire.com/prnh/20130307/600769 ... global digital media watermarking and fingerprinting markets. Watermarking ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... http://photos.prnewswire.com/prnh/20130307/600769 ... introduced the fingerprint reading feature with the iPhone 5S. ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
Other Contents